A subscription to JoVE is required to view this content. Sign in or start your free trial.
This article describes a procedure to produce iTenocytes by generating iPSC-derived mesenchymal stromal cells with combined overexpression of Scleraxis using a lentiviral vector and uniaxial stretching via a 2D bioreactor.
Today's challenges in tendon and ligament repair necessitate the identification of a suitable and effective candidate for cell-based therapy to promote tendon regeneration. Mesenchymal stromal cells (MSCs) have been explored as a potential tissue engineering strategy for tendon repair. While they are multipotent and have regenerative potential in vivo, they are limited in their self-renewal capacity and exhibit phenotypic heterogeneity. Induced pluripotent stem cells (iPSCs) can circumvent these limitations due to their high self-renewal capacity and unparalleled developmental plasticity. In tenocyte development, Scleraxis (Scx) is a crucial direct molecular regulator of tendon differentiation. Additionally, mechanoregulation has been shown to be a central element guiding embryonic tendon development and healing. As such, we have developed a protocol to encapsulate the synergistic effect of biological and mechanical stimulation that may be essential for generating tenocytes. iPSCs were induced to become mesenchymal stromal cells (iMSCs) and were characterized with classic mesenchymal stromal cell markers via flow cytometry. Next, using a lentiviral vector, the iMSCs were transduced to stably overexpress SCX (iMSCSCX+). These iMSCSCX+ cells can be further matured into iTenocytes via uniaxial tensile loading using a 2D bioreactor. The resulting cells were characterized by observing the upregulation of early and late tendon markers, as well as collagen deposition. This method of generating iTenocytes can be used to assist researchers in developing a potentially unlimited off-the-shelf allogeneic cell source for tendon cell therapy applications.
To tackle the contemporary issues in tendon and ligament repair, there's a requirement for a pertinent cell candidate suitable for cell-based therapies. One avenue of investigation in tissue engineering for tendon repair involves the exploration of bone marrow-derived mesenchymal stromal cells (BM-MSCs) and adipose tissue-derived stromal cells (ASCs) as potential strategies. These cells have multipotent capability, great abundance, and regenerative potential in vivo. Additionally, they have shown enhanced healing capacity and improved functional outcomes in animal models1. Nonetheless, these cells exhibit restricted self-renewal ca....
This protocol to produce iTenocytes can be conducted in three major steps: iPSCs to iMSCs (10 days), iMSC to iMSCSCX+ (2 weeks), iMSCSCX+ to iTenocytes (minimum 4 days). Each major step in the protocol can be paused and restarted later, depending on the experimental timeline. For methods involved with culturing of cells, sterile techniques should be employed. All cells in this protocol should be grown at 37 °C, 5% CO2, and 95% humidity.
1. Human iPSC.......
Human iPSCs differentiation to iMSCs
As previously described, the current protocol for differentiating iPSCs into iMSCs involves the formation of embryoid bodies2. This process takes approximately ten days to induce iMSCs from iPSCs (Figure 1A). However, it is highly recommended to passage the newly generated iMSCs at least twice. This not only helps eliminate the need for gelatin-coated plates but also establishes stable MSC expression. Flow cy.......
In this protocol, iTenocytes are generated through three main steps: (1) induction of iPSCs to iMSCs, (2) overexpression of SCX using a lentiviral vector, and (3) maturation of cells through 2D uniaxial tension.
The protocol presented for differentiating iPSCs into iMSCs has been previously described by our group2. Since that publication, numerous protocols have been developed, including an established protocol for using iMSCs in clinical trials21
This study was partially supported by the NIH/NIAMS K01AR071512 and CIRM DISC0-14350 to Dmitriy Sheyn. The two lentivirus packaging plasmids were a gift from the Simon Knott laboratory (Department of Biomedical Sciences, Cedars-Sinai Medical Center).
....Name | Company | Catalog Number | Comments |
2-mercaptoethanol | Sigma Aldrich | M3148 | |
Accutase | StemCell Technologies | 7920 | cell dissociation reagent |
Antibiotic-antimycotic solution | Thermofisher | 15240096 | |
Anti-CD105 | Ancell | 326-050 | |
APC mouse anti-human CD44 | BD Biosciences | 559942 | |
APC mouse IgG2 K isotype control | BD Biosciences | 555745 | |
BenchMark fetal bovine serum | GeminiBio | 100-106 | |
Biglycan | Thermofisher | Hs00959143_m1 | |
Bovine serum albumin | Millipore Sigma | A3733 | |
Collagen type I alpha 1 chain human Taqman primer | Thermofisher | Hs00164004_m1 | |
Collagen type III alpha 1 chain human Taqman primer | Thermofisher | Hs00943809_m1 | |
Dimethyl sulfoxide | Millipore Sigma | D8418 | |
DMEM, low glucose, pyruvate, no glutamine, no phenol red | Thermofisher | 11054020 | |
Eagle's minimum essential medium (EMEM) | ATCC | 30-2003 | |
Fibronectin bovine plasma | Sigma Aldrich | F1141 | |
FITC mouse anti-human CD90 | BD Biosciences | 555595 | |
Gelatin from porcine skin | Sigma Aldrich | G1890 | |
Goat anti Mouse IgG1-PE | Bio-Rad | STAR117 | |
HEK 293T/17 | ATCC | CRL-11268 | |
IMDM, no phenol red | Thermofisher | 21056023 | |
iPSCs: 83i-cntr-33n1 | Cedars-Sinai iPSC Core Facility | N/A | https://biomanufacturing.cedars-sinai.org/product/cs83ictr-33nxx/ |
Isotype Control Antibody, mouse IgG2a-FITC | Miltenyi Biotec | 130-113-271 | |
KnockOut serum replacement | Thermofisher | 10828010 | |
L-ascorbic acid | Sigma Aldrich | A4544 | |
L-Glutamine | Thermofisher | 2503081 | |
Matrigel | Corning | 354230 | basement membrane matrix |
MechanoCulture FX | CellScale | N/A | stretching apparatus |
MEM non-essential amino acids solution | Thermofisher | 11140050 | |
Mohawk human Taqman primer | Thermofisher | Hs00543190_m1 | |
mTeSR Plus | StemCell Technologies | 100-0276 | |
PBS | Thermofisher | 10010023 | |
Platelet-derived growth factor receptor A human Taqman primer | Thermofisher | Hs00998018_m1 | |
Poly(2-hydroxyethyl methacrylate) | Sigma Aldrich | 192066 | |
Polybrene infection/transfection reagents | Millipore Sigma | TR-1003 | |
Recombinant human TGF-beta 1 protein human Taqman primer | RnD Systems | 240-B | |
Scleraxis human Taqman primer | Thermofisher | Hs03054634_g1 | |
SCXA (SCX) (NM_00108050514) human tagged ORF clone | OriGene | RC224305L4 | |
Silicone plates | CellScale | N/A | |
Sodium azide | Millipore Sigma | S2002 | |
Tenascin C human Taqman primer | Thermofisher | Hs00370384_m1 | |
Tenomodulin human Taqman primer | Thermofisher | Hs00223332_m1 | |
Thrombospondin 4 human Taqman primer | Thermofisher | Hs00170261_m1 | |
Transfection reagent, BioT | Bioland Scientific LLC | B01-01 | |
Trypsin-EDTA (0.25%) | Thermofisher | 25200072 | |
Tubulin polymerization promoting protein family member 3 | Thermofisher | Hs03043892_m1 | |
Y-27632 dihydrochloride | Biogems | 1293823 |
This article has been published
Video Coming Soon
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved